Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study
Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute e...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S104366182200319X |
| _version_ | 1797366611774013440 |
|---|---|
| author | Elisa Lazzaroni Maria Elena Lunati Laura Montefusco Ida Pastore Enrica Chebat Vincenzo Cimino Paola Silvia Morpurgo Milena Muratori Laura Plebani Andrea Bolla Antonio Rossi Luciana Vallone Alessandra Gandolfi Camilla Tinari Francesca D’Addio Moufida Ben Nasr Cristian Loretelli Cristiana Scaranna Rosalia Bellante Roberto Manfrini Fabrizio Muratori Ivano Franzetti Emanuela Orsi Carmine Gazzaruso Renata Ghelardi Paolo Desenzani Stefano Genovese Angela Girelli Franco Folli Cesare Berra Paolo Fiorina |
| author_facet | Elisa Lazzaroni Maria Elena Lunati Laura Montefusco Ida Pastore Enrica Chebat Vincenzo Cimino Paola Silvia Morpurgo Milena Muratori Laura Plebani Andrea Bolla Antonio Rossi Luciana Vallone Alessandra Gandolfi Camilla Tinari Francesca D’Addio Moufida Ben Nasr Cristian Loretelli Cristiana Scaranna Rosalia Bellante Roberto Manfrini Fabrizio Muratori Ivano Franzetti Emanuela Orsi Carmine Gazzaruso Renata Ghelardi Paolo Desenzani Stefano Genovese Angela Girelli Franco Folli Cesare Berra Paolo Fiorina |
| author_sort | Elisa Lazzaroni |
| collection | DOAJ |
| description | Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (−0.6 ± 1.8%) as well as in BMI (−1.5 ± 5.2 kg/m2). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D. |
| first_indexed | 2024-03-08T17:07:14Z |
| format | Article |
| id | doaj.art-bebdf59a7df04d4580f983cb409b28c8 |
| institution | Directory Open Access Journal |
| issn | 1096-1186 |
| language | English |
| last_indexed | 2024-03-08T17:07:14Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj.art-bebdf59a7df04d4580f983cb409b28c82024-01-04T04:38:07ZengElsevierPharmacological Research1096-11862022-09-01183106374Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE studyElisa Lazzaroni0Maria Elena Lunati1Laura Montefusco2Ida Pastore3Enrica Chebat4Vincenzo Cimino5Paola Silvia Morpurgo6Milena Muratori7Laura Plebani8Andrea Bolla9Antonio Rossi10Luciana Vallone11Alessandra Gandolfi12Camilla Tinari13Francesca D’Addio14Moufida Ben Nasr15Cristian Loretelli16Cristiana Scaranna17Rosalia Bellante18Roberto Manfrini19Fabrizio Muratori20Ivano Franzetti21Emanuela Orsi22Carmine Gazzaruso23Renata Ghelardi24Paolo Desenzani25Stefano Genovese26Angela Girelli27Franco Folli28Cesare Berra29Paolo Fiorina30Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy; Centre for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università Degli Studi Milano, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyCentre for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università Degli Studi Milano, Milan, Italy; Endocrinology and Diabetology, Pio Albergo Trivulzio, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy; Centre for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università Degli Studi Milano, Milan, ItalyCentre for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università Degli Studi Milano, Milan, ItalyCentre for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università Degli Studi Milano, Milan, ItalyDivision of Endocrinology and Diabetology, ASST Papa Giovanni XXIII, Bergamo, ItalyDivision of Endocrinology and Diabetology, ASST Papa Giovanni XXIII, Bergamo, ItalyEndocrinology and Metabolism, Department of Health Science, Università degli Studi di Milano, Milan, Italy; Departmental Unit of Diabetes and Metabolism, San Paolo Hospital, ASST Santi Paolo e Carlo, ItalyDivision of Endocrinology and Diabetology, Sant'Anna Hospital - ASST Lariana, Como, ItalyDivision of Endocrinology and Diabetology, S. Antonio Abate Hospital, Gallarate, ItalyDiabetes Service, Endocrinology and Metabolic Diseases Unit, IRCCS ''Cà Granda - Ospedale Maggiore Policlinico'' Foundation, ItalyDiabetes and Endocrine, Metabolic and Vascular Diseases Unit and the Centre for Applied Clinical Research (Ce.R.C.A.) Clinical Institute ''Beato Matteo'' (Hospital Group San Donato), Vigevano, ItalyUnit of Diabetology, ASST Melegnano-Martesana, San Giuliano Milanese, ItalyUnit of Diabetology, ASST Spedali Civili, Montichiari, Brescia, ItalyCentro Cardiologico Monzino IRCCS, 20138 Milan, ItalyUnit of Diabetology, Spedali Civili, Brescia, ItalyEndocrinology and Metabolism, Department of Health Science, Università degli Studi di Milano, Milan, Italy; Departmental Unit of Diabetes and Metabolism, San Paolo Hospital, ASST Santi Paolo e Carlo, ItalyDepartment of Endocrinology, Nutrition and Metabolic Diseases, IRCCS Multimedica, Milan, ItalyDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy; Centre for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università Degli Studi Milano, Milan, Italy; Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Correspondence to: Nephrology Division, Boston Children’s Hospital, 300 Longwood Ave, Boston, MA 02115, USA.Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (−0.6 ± 1.8%) as well as in BMI (−1.5 ± 5.2 kg/m2). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D.http://www.sciencedirect.com/science/article/pii/S104366182200319XDapagliflozinHb1AcAlbuminuriaCardio-vascular risk |
| spellingShingle | Elisa Lazzaroni Maria Elena Lunati Laura Montefusco Ida Pastore Enrica Chebat Vincenzo Cimino Paola Silvia Morpurgo Milena Muratori Laura Plebani Andrea Bolla Antonio Rossi Luciana Vallone Alessandra Gandolfi Camilla Tinari Francesca D’Addio Moufida Ben Nasr Cristian Loretelli Cristiana Scaranna Rosalia Bellante Roberto Manfrini Fabrizio Muratori Ivano Franzetti Emanuela Orsi Carmine Gazzaruso Renata Ghelardi Paolo Desenzani Stefano Genovese Angela Girelli Franco Folli Cesare Berra Paolo Fiorina Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study Pharmacological Research Dapagliflozin Hb1Ac Albuminuria Cardio-vascular risk |
| title | Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study |
| title_full | Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study |
| title_fullStr | Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study |
| title_full_unstemmed | Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study |
| title_short | Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study |
| title_sort | dapagliflozin acutely improves kidney function in type 2 diabetes mellitus the precare study |
| topic | Dapagliflozin Hb1Ac Albuminuria Cardio-vascular risk |
| url | http://www.sciencedirect.com/science/article/pii/S104366182200319X |
| work_keys_str_mv | AT elisalazzaroni dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT mariaelenalunati dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT lauramontefusco dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT idapastore dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT enricachebat dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT vincenzocimino dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT paolasilviamorpurgo dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT milenamuratori dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT lauraplebani dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT andreabolla dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT antoniorossi dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT lucianavallone dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT alessandragandolfi dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT camillatinari dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT francescadaddio dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT moufidabennasr dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT cristianloretelli dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT cristianascaranna dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT rosaliabellante dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT robertomanfrini dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT fabriziomuratori dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT ivanofranzetti dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT emanuelaorsi dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT carminegazzaruso dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT renataghelardi dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT paolodesenzani dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT stefanogenovese dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT angelagirelli dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT francofolli dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT cesareberra dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy AT paolofiorina dapagliflozinacutelyimproveskidneyfunctionintype2diabetesmellitustheprecarestudy |